- Among patients treated with OTEZLA 30 mg BID, improvements in pruritus VAS scores correlated with DLQI scores (rs = 0.55 [week 16]; rs ≥ 0.51 [week 32]; P < 0.001)1
This site is intended for healthcare professionals outside the U.S.
ESTEEM® 1 study. Data as observed from patients in the full analysis set. Results were consistent between ESTEEM 1 and ESTEEM 2.
Pruritus was measured on a 100-mm VAS. Baseline values: Placebo, 65.0 mm; OTEZLA 30 mg BID, 66.1 mm.
BL, baseline; DLQI, Dermatology Life Quality Index; ESTEEM, Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; VAS, visual analogue scale.
Reference: 1. Sobell JM, Foley P, Toth D, et al. Effects of Apremilast on Pruritus and Skin Discomfort/Pain Correlate With Improvements in Quality of Life in Patients With Moderate to Severe Plaque Psoriasis. Acta Derm Venereol. 2016;96(4):514-20.
Please choose a country